Brief: Transgene H1 Net Comprehensive Loss At 2.2 Million Euros

Transgene SA

16/09/2020 16:53

Sept 16 (Reuters) - TRANSGENE SA  TRNG.PA :
    * H1 REVENUE 5.7 MILLION EUR VERSUS 4.9 MILLION EUR YEAR AGO
    * TG4001: VERY PROMISING RESULTS FROM PHASE 1B/2 TRIAL IN
HPV-POSITIVE CANCERS
    * TG6002: INITIAL TRANSLATIONAL RESULTS CONFIRM VALUE OF
INTRAVENOUS ADMINISTRATION
    * PRECLINICAL AND CLINICAL PROJECTS PROGRESSING DESPITE
COVID-19
PANDEMIC
    * EUR 33.2 MILLION OF CASH AT END OF JUNE 2020
    * SUCCESSION OF CHAIRMAN AND CHIEF EXECUTIVE OFFICER PLANNED
AT
END OF 2020
    * OPERATING REVENUES AMOUNTED TO EUR 5.7 MILLION FOR FIRST
SIX
MONTHS OF 2020
    * NET INTEREST INCOME AMOUNTED TO A GAIN OF EUR 9.2 MILLION
IN
FIRST HALF OF 2020
    * NET COMPREHENSIVE LOSS AMOUNTED TO EUR 2.2 MILLION FOR
FIRST
HALF OF 2020
    * AS OF JUNE 30, 2020,  CASH, CASH EQUIVALENTS AND OTHER
FINANCIAL
ASSETS AMOUNTED TO EUR 33.2 MILLION VERSUS EUR 43.3 MILLION AS
OF DECEMBER 31, 2019
    * INTENDS TO REIMBURSE EUR 10 MILLION BANK LOAN FROM
EUROPEAN
INVESTMENT BANK IN ADVANCE OF ITS JUNE 2021 MATURITY.
    * CONFIRMS ITS FINANCIAL VISIBILITY UNTIL 2022.

Source text for Eikon:  ID:nBw47yzk4a 
Further company coverage:  TRNG.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))